T

he foundational patents on the CRISPR-Cas9 technology remain hung up in an ugly legal fight. But applications for new patents on specific uses of the genome-editing system continue to be filed.

The latest, published on Thursday but first filed in 2013, covers the use of CRISPR-Cas (it’s broader than just Cas9) in what are called nucleotide repeat disorders — basically, inherited diseases in which DNA stutters: A gene includes hundreds, instead of just a few, repeats of strings of letters such as CAG or CGG.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy